To amend the Public Health Service Act to ensure that a woman seeking a chemical abortion is made aware of the risks involved, and for other purposes.

Legislative bill overview

HR 7237 would amend the Public Health Service Act to require that women seeking medication abortion (chemical abortion) receive information about associated risks before the procedure. The bill was introduced in January 2026 and referred to the House Committee on Energy and Commerce for consideration.

Why is this important

Medication abortion access and informed consent requirements are contentious healthcare policy issues. The bill directly affects how abortion providers must communicate with patients and potentially impacts the regulatory framework governing medication abortion, which accounts for a significant and growing portion of abortions in the United States.

Potential points of contention

• Informed consent scope: Disagreement over what constitutes adequate risk disclosure—supporters argue comprehensive risk information is essential; critics contend it may include disputed or overstated risks that discourage access
• Medical practice standards: Debate about whether federal legislation should mandate specific patient communication protocols versus allowing medical professional judgment and existing state regulations
• Abortion access vs. safety framing: Differing perspectives on whether such requirements primarily serve patient safety or function as barriers to abortion access